Deep data combined with AI turns a revelation into a revolution

Unrivaled scientific capabilities turn IndivuType into a unique asset for making novel discoveries in oncology.

By combining our proprietary, unique multi-omics and clinical datasets with AI-assisted advanced analytics, we drive biomarker discovery and novel target identification and validation for potential therapies – using the same high-quality data and tissue all the way through.

Unique tissue samples provide unique data

Our Global
Clinical Network

Only through our worldwide network of selected partner clinics is it possible to collect tissue samples and clinical data that meet our high-quality standards.

The key to this are globally implemented standard operating procedures (SOPs) ensuring all clinical framework conditions are precisely fulfilled.

Therefore, our biospecimen reflect the molecular reality of cancer to an unparalleled level.

Explore more

Our Multi-omics
Cancer Database

By combining multi-omics and clinical data we can drive in-silico research and development in cancer treatment, such as:

  • discovery of new therapeutic drug targets, and
  • assessment of molecular signaling pathways or identification of biomarkers and gene signatures for stratification of cancer patients.

Standardized Collection
and Processing

The uniqueness of our samples is a result of standard collection and processing. Cold ischemia times of <10 minutes and collection of tumor and adjacent normal tissue from the same patient make our data unique.

Alongside the tissue, around 320 different clinical data points are collected.

Data Generation

The high quality of our tissue samples therefore allows us to use a full multi-omics approach (proteomics, phosphoproteomics, transcriptomics, genomics, and miRNA).

Using next-generation sequencing and mass spectrometry technologies, we extract the deepest possible molecular information from tissue samples.

In-depth Data

The raw data is quality controlled and processed with state-of-the-art technology and infrastructure, making it ready for cloud-based AI analysis.

Advancing Precision

Increasing the reliability, quality, and reproducibility of the data, our database constitutes an unparalleled resource with which to speed up discovery and development.

The powerful discovery machine

The unique clinical data is combined with multi-omics data and deciphered via our AI-driven analysis platform nRavel®. The goal is to extract therapeutic targets and validate them not only in-silico, but also in-vitro.

nRavel® Rx: Target Identification and Validation,
In-silico and In-vitro

Using nRavel’s unique analytical power to identify and validate new therapeutic drug targets.

Patient Based
Target Discovery

Through combining multi-omic expression signatures and prognostic data in selected cohorts, we identify targets that are further characterized and subsequently prioritized using nRavel®.

Patient Based
Cellular Models

Once a therapeutic drug target candidate has been successfully validated in-silico, the next step is to validate them in-vitro on 2D and 3D cell models derived from the original cohort used for the in-silico analyses.

nRavel® Dx: Optimized Clinical Study Design

Benefit from our experience and resources.

Tailor-made Study Design
for Your Target

Using nRavel® and our multi-omics and clinical database, the design for the clinical study can be optimized for each individual drug as the in-depth knowledge of the molecule defines the patient selection.

Partner with us

In order to truly individualize cancer therapy, we partner with you to provide our expertise, capabilities, and insight knowledge throughout the whole development process.

Get in touch

We have successfully established partnerships with small biotech as well as large pharmaceutical companies and prestigious academic institutions, both enhancing R&D activities and launching new discovery programs.

Please contact us in case you want to discuss a collaboration or if you want to hear more about our internal biomarker and target discovery pipeline.